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Posttransplant lymphoproliferative disorders (PTLDs) are a group of diseases that range from benign polyclonal to malignant
monoclonal lymphoid proliferations. They arise secondary to treatment with immunosuppressive drugs given to prevent
transplant rejection. Three main pathologic subsets/stages of evolution are recognised: early, polymorphic, and monomorphic
lesions. The pathogenesis of PTLDs seems to be multifactorial. Among possible infective aetiologies, the role of EBV has been
studied in depth, and the virus is thought to play a central role in driving the proliferation of EBV-infected B cells that leads
to subsequent development of the lymphoproliferative disorder. It is apparent, however, that EBV is not solely responsible
for the “neoplastic” state. Accumulated genetic alterations of oncogenes and tumour suppressor genes (deletions, mutations,
rearrangements, and ampliﬁcations) and epigenetic changes (aberrant hypermethylation) that involve tumour suppressor genes
are integral to the pathogenesis. Antigenic stimulation also plays an evident role in the pathogenesis of PTLDs. Plasmacytoid
dendritic cells (PDCs) that are critical to ﬁght viral infections have been thought to play a pathogenetically relevant role in PTLDs.
Furthermore, regulatory T cells (Treg cells), which are modulators of immune reactions once incited, seem to have an important
role in PTLDs where antigenic stimulation is key for the pathogenesis.
1.Introduction
Post-transplant lymphoproliferative disorders (PTLDs) are a
groupofdiseasesthatrangefrombenignpolyclonaltomalig-
nant monoclonal lymphoid proliferations. They develop as
a consequence of immunosuppression. PTLDs are charac-
terised by the following: they are usually derived from B cells
with preferential presentation as non-Hodgkin’s lymphoma
(as against Hodgkin’s lymphoma), usually originate in
extranodal sites, rarely aﬀect skin, behave aggressively, and
frequently harbour the Epstein-Barr virus (EBV) genome.
Whilstmostarehigh-gradeB-cellnon-Hodgkin’s lymphoma
(NHLs), a few are classical Hodgkin’s lymphomas. Rare cases
havealsobeenshowntobeeitherofT-cellorNK-celllineages
[1, 2].
T-cell neoplasms constitute 10% to 15% of all PTLDs,
and about 75% of T-cell PTLDs, have been shown to be
negative for EBV and to behave more aggressively. T-PTLDs
usually develop later than B-PTLDs and patients are less
likely to respond to reduction in immunosuppression [3, 4].
The abnormal B cells in solid organ transplant recipients
originate usually from those of the recipient, while in
recipients of bone marrow transplant they are of donor
origin [5, 6].
2.Onset,Frequencyof Occurrence,and
Risk Factorsof PTLD
PTLDs are classiﬁed as either early onset lesions which
develop within one year, or late onset lesions, which develop
more than one year after transplantation [7, 8].
TheoccurrenceofPTLDvariesbetweendiﬀerentstudies,
but the overall frequency is less than 2% in transplant
recipients [9]. It diﬀers according to many factors such as the
age of the patient, the organ transplanted, type and dosage2 Advances in Hematology
regimen of immunosuppressive drugs, and the pretransplant
EBV serostatus [10].
(1) The age of the patient. children are more prone to devel-
oping PTLDs as they are usually na¨ ıve for Epstein-Barr virus
(EBV) infection [10].
(2) The organ transplanted. the frequency of PTLD diﬀers
according to the type of organ transplanted. (Table 1)s u m -
marizes the frequency of PTLDs in transplant recipients
[6, 9].
(3) Type and dosage regimen of immunosuppressive drugs. It
has been reported that the risk of developing PTLD increases
with the use of certain drugs such as tacrolimus and OKT3,
especially when they are combined [11]. Despite the fact
that immunosuppressive drugs are an established risk factor,
it is still not well-understood whether the risk is due to
the cumulative dose or peak levels of immunosuppressive
drugs. The cumulative dose, however, is more likely to be the
incriminating factor [12].
(4) The pretransplant EBV sero-status. EBV-naive recipients,
being incapable of initiating an EBV-speciﬁc cytotoxic T-
l y m p h o c y t e( C T C )r e s p o n s e ,a r em o r el i a b l et od e v e l o p
PTLD [12, 13]. Nonexposure to EBV before transplantation
remains the most important predisposing factor [13].
3. ClinicalPresentation
The clinical manifestations vary from nonspeciﬁc symptoms
in the form of fever, sweats, malaise, weight loss, and features
of primary EBV infection in some patients, to sudden en-
largement of tonsils, lymph nodes, or other extranodal lym-
phoid organs. Other organs such as the central nervous
system, bone marrow, spleen, lung, small intestine, liver, and
kidney may also be aﬀected [10].
4.Pathological FeaturesandClassiﬁcation
of PTLDs
Clinicopathologic features of major types of posttransplant
lymphoproliferative disorders are summarised in Table 2.
The classiﬁcation of PTLDs is currently based on the WHO
classiﬁcation of lymphoid neoplasms (Table 3). Three main
pathologic subsets/stages of evolution are recognised: early,
polymorphic, and monomorphic lesions [3].
4.1. Early Lesions. Early lesions form one end of the spec-
trum of PTLD and mostly develop within one year after
transplantation. These include two morphological types:
plasma cell hyperplasia and infectious mononucleosis-like
lesions. Early lesions more frequently involve tonsils, ade-
noidsorlymphnodesthantrueextranodalsites.Theydonot
invade or disturb the architecture of the aﬀected tissue [3].
Plasmacytic hyperplasia shows numerous polytypic
plasmacellsandoccasionalimmunoblasts. Infectiousmono-
Table 1: Frequency of PTLD in diﬀerent types of transplants.
Organ
transplanted
Reported risk of developing
PTLD % and references
Kidney 1%
Liver 2–5%
Heart 2–5%
Lung 1.8–7.9%
Heart-lung 9.4%
Small bowel up to 30%
Pancreas 2.1%
Bone marrow <1%
nucleosis-like lesions show marked paracortical expansion
by a cellular inﬁltrate composed of numerous immunoblasts
and a mixed population of T cells and plasma cells. These
lesions often show spontaneous regression or regress fol-
lowing reduction in immunosuppression [3]. Immunoblasts
in infectious mononucleosis-like lesions frequently harbour
EBV and express EBV-encoded RNA (EBER) or EBV-LMP-1.
Early lesions rarely harbour clonal cytogenetic changes [14].
4.2. Polymorphic PTLDs. Polymorphic PTLDs aﬀect nodal
and extranodal tissues and show loss of tissue architecture
and necrosis. Polymorphic PTLDs are composed of a mixed
population of immunoblasts, plasma cells, intermediate-
sized lymphoid cells (incorporating a full range of B-
cell morphology and diﬀerentiation), as well as occasional
Hodgkin Reed Sternberg-like cells [15]( Figure 1). The B-
cells are usually monotypic but may be polytypic. Nonethe-
less, a clonal pattern of IgH or episomal EBV genome is
observed [16, 17]. The majority of the lesions exhibit EBV
latency type II or III (expressing EBER and EBV-LMP-1 with
variable expression of EBV-EBNA2 and other viral antigens).
A variable proportion of cases show regression in response
to reduction in immune suppression while other cases may
progress and require chemotherapy [3].
4.3.MonomorphicPTLDs. MonomorphicPTLDs(mPTLDs)
can be either of B cell or T-cell lineage and resemble
the typical types of non-Hodgkin lymphomas (NHLs)
seen in immunocompetent patients, and they are usually
monoclonal. They disturb the tissue architecture and spread
to other organs. They are classiﬁed according to the WHO
classiﬁcation of lymphomas in immunocompetent patients.
Monomorphic B-PTLDs show features of diﬀerent morpho-
logic variants of diﬀuse large B-cell lymphoma (DLBCL)
in immunocompetent patients (iDLBCL) (immunoblastic,
centroblastic, or anaplastic), Burkitt’s lymphoma (BL), or
plasmablastic lymphoma (PL). Almost all cases display a
clonalpatternofIGH rearrangement,andEBV-positivecases
show episomal EBV genome. mPTLDs can be EBV-negative,
tend to be more aggressive, and only rarely respond to
a reduction in immune suppression [3, 18]. In addition,
genetic alterations of 3q27, 8q24.1, and 14q32 have been
described in monomorphic B-PTLDs [19]. The identiﬁca-
tion of similar cytogenetic alterations and clonal relationshipAdvances in Hematology 3
(a) (b) (c)
(d) (e) (f)
Figure 1: A typical case of polymorphic PTLD. (a) Inﬁltrate is a mix of plasma cells, small lymphoid cells and larger cells with nucleoli. The
cells are positive for CD20 (b), CD30 (c), MUM1 (d), EBER (e), and EBV-LMP-1. Magniﬁcation: (b,d): ×100; (a,e,f): ×200.
Table 2: Clinicopathologic features of major types of posttransplant lymphoproliferative disorders.
Early lesions (plasmacytic hyperplasia
and infectious mononucleosis-like) Polymorphic PTLD Monomorphic PTLD
(i) Clinical features
(a) Age Children and young adults All age groups All age groups
(b) Organ involved Tonsils or lymph nodes L y m p hn o d e s ,G I T ,l u n go r
allograft
Lymph node, any
extranodal site, including
bone marrow
(c) Regression
Usually regress either with minimal
reduction of immunosuppressive
drugs or spontaneously
Some cases regress, others
progress
Very rare. Most cases
progress rapidly
(ii) Histopathological features
(a) Tissue architecture No or partial eﬀacement Nearly complete eﬀacement Complete eﬀacement
(b) Nature of inﬁltrate
Comprised mainly of plasma cells and
lymphoplasmacytoid cells in
plasmacytic hyperplasia, and
immunoblasts and plasmablasts in
infectious mononucleosis-like lesion
Composed of a mixture of
plasma cells, small
lymphocytes, and large
activated cells
Monotonous, similar to
that of usual type B-cell
NHL
(c) Atypia Absent Present/absent in large cells Present
(d) Necrosis Absent Variable Present (geographic)
(iii) Molecular features
(a) Ig gene Polyclonal in most cases Usually monoclonal; may
be oligo or polyclonal Monoclonal
(b) EBV Usually nonclonal Clonal Clonal
(c) Structural alterations of
oncogenes and TSG Usually absent Usually absent Usually present
Ig:immunoglobulin,EBV:Epstein-Barrvirus,PTLD:posttransplantlymphoproliferativedisorder,NHL:non-Hodgkin’slymphoma,TSG:tumoursuppressor
gene.4 Advances in Hematology
Table 3: Categories of posttransplant lymphoproliferative disor-
ders.
(1) Early lesions
(a) Reactive plasmacytic hyperplasia
(b) Infectious mononucleosis-like lesions
(2) Polymorphic PTLD
(3) Monomorphic PTLD
(classiﬁed according to lymphoma they resemble)
B-cell neoplasms
(a) Diﬀuse large B-cell lymphoma (DLBCL)
(b) Burkitt’s lymphoma
(c) Plasma cell myeloma
(d) Plasmacytoma-like lesions
(e) Others∗
T-cell neoplasms
(a) Peripheral T-cell lymphoma not otherwise speciﬁed
(b) Hepatosplenic T-cell lymphoma
(c) Others
(4) Classical Hodgkin’s lymphoma-type (HL-PTLD)
and HL-like PTLD∗∗
∗IndolentsmallB-celllymphomasdevelopingintransplantrecipientarenot
included among the PTLD.
∗∗HL-like PTLDs are better categorized either as a polymorphic or mono-
morphic PTLD based on the overall morphology.
between polymorphic PTLDs and mPTLD supports the
hypothesis that PTLDs progress along a continuum from
polyclonal early lesions to monoclonal mPTLD [3, 20].
Plasmablastic lymphomas (PBL), which were originally
described in HIV-infected people aﬀecting the oral cavity,
may occur as a PTLD. Nearly 60–75% of cases of PBL are
EBV associated [21–23].
T h e r ea r eo n l yaf e wc a s e so fP T L D sr e p o r t e di nt h e
literature that demonstrate both B- and T-cell clones. In a re-
cently published study, however, monoclonal expansion
of T-cell population which seems to arise from CD8+ T
cells has been found to occur frequently in B-PTLDs, and
these clonal T-cell populations coexist with monoclonal B-
cell population in B-PTLDs. However, these clonal T-cell
expansionsdonotconstituteaclinicalT-celllymphoma[24–
26].
4.4. Hodgkin’s Lymphoma-PTLD and HL-Like PTLD. The
histological features of HL-type PTLD are similar to mixed
cellularity or lymphocyte-depleted subtypes. The inﬁltrate is
composed of scattered large pleomorphic mono- and binu-
cleated Hodgkin/Reed-Sternberg giant cells in a background
of small lymphocytes, B-immunoblasts intermingled with
histiocytes, plasma cells, a few eosinophils, and neutrophils.
The neoplastic cells are usually CD30+, and CD15+,E B E R +,
CD45−,O C T - 2 −/BOB1 [3]. In HL-like PTLD, the EBV+
cells are CD45+, CD20+, and CD15+ and EBV+ small and
medium-sizedlymphoidcellsmaybepresent.Distinguishing
HL-PTLD from HL-like lesions is sometimes diﬃcult, and
it has been suggested that the latter are better diagnosed as
either a polymorphic or monomorphic PTLD based on the
overall morphological features [3].
5.Aetiology andPathogenesis
The pathogenesis of PTLD is multifactorial. EBV plays an
important role in driving the proliferation of EBV-infected
B cells. It is widely perceived, however, that it is not solely
responsible for the “neoplastic” state, and that accumulation
of diﬀerent aberrations in protooncogenes and suppressor
genes, and hypermethylation of suppressor genes are integral
parts of the pathogenesis [27]( Figure 2).
5.1. Viruses
5.1.1.EBV. EBVisanoncogenicdouble-strandedDNAvirus
that infects and persists in memory B cells. Two phases
of EBV infection have been recognized. The lytic phase is
characterizedbytheexpressionofallEBVproteinsandactive
viral replication, leading eventually to cell death and the
release of virions. The latency phase involves infection of
lymphoid B cells via their CD21 receptors, resulting in the
formation of EBV episomes and the expression of a limited
number of viral proteins [28].
This results in persistence of the virus in the lymphoid
cells and their progeny without destruction of the infected
cell. LMP-1 and LMP-2 viral proteins are believed to act
as oncogenes, allowing B cells to escape cell death and
proliferate autonomously [28]. There are three diﬀerent
latency patterns that correspond to the diﬀerentiation stages
of B cells. These patterns are thought to play a major role in
protectingEBV-infectedcellsfromimmunosurveillance[29–
31]. EBV-infected naive B cells expressing all latent antigens
are said to have “type III latency.” Infected naive B cells
enter the germinal centre where they multiply and form
clones. They express EBNA1, LMP-1, and LMP-2, and this is
k n o w na s“ t y p eI Il a t e n c y ”[ 32]. However, some only express
EBNA-1and2aswellassmallnoncodingEpstein-BarrRNAs
( E B E R S )a n da r es a i dt oh a v e“ t y p eIl a t e n c y ”a ss e e ni n
Burkitt’s lymphoma [33, 34].
Most PTLDs are associated with EBV, but nonetheless
a proportion (42% reported in one study) is EBV-negative,
including53%ofthemPTLDcases[35,36].Thereisadebate
as to whether EBV-negative PTLDs are in fact incidental
lymphomasdeveloping intransplantpatients,ortruePTLDs
that can regress following reduction of the immunosuppres-
sion [37]. It has to be noted that the lack of identiﬁable
EBV, based on EBER or LMP-1 staining, does not necessarily
imply that EBV-DNA is absent in all of these cases, or that
EBV did not play a role in the pathogenesis of the EBV-
negative lymphoid proliferations [38]. It has been suggested
that EBV-negative PTLD may develop as a result of “hit and
run” oncogenesis as does EBV-negative classical Hodgkin
lymphoma (cHL) [38, 39]. Chronic antigenic stimulation on
the background of immune suppression is thought to play
an essential role in the pathogenesis of EBV-negative PTLD
[40].Advances in Hematology 5
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Figure 2: A proposed model of pathogenesis of EBV infection in the development of PTLDs in sold organ transplant recipients. CTL:
cytotoxic T lymphocytes, IL-10: interleukin-10, INF-α: Interferon-α, NK cells: natural killer cells, PDC: plasmacytoid dendritic cells, TLR-9:
toll-like receptor-9.
B-PTLDs have been shown to be more frequently associ-
ated with type-A EBV genotype than type-B EBV [41, 42].
5.1.2. HHV-8. HHV-8 is a gamma-herpes virus that, like
EBV,infectsBcellsandacquiresanepisomalconﬁgurationin
the nucleus and results in a state of latency. In the posttrans-
plant setting, it has only been detected in cases of primary
eﬀusion lymphoma [43, 44]. In a recently published study,
KSHV/HHV-8 was found to be consistently absent in PTLD
[45].
5.2. Molecular Alteration of Cellular Genes. Diﬀerent genetic
alterations among PTLDs are summarised in Table 4.
5.2.1. Microsatellite Instability. Lymphomas developing in
immunocompetent patients are often characterized by rela-
tive genomic stability. In contrast, a small subset of PTLD is
associated with microsatellite instability, which results from
defects in DNA mismatch repair mechanisms [46]. These
cases show mutations involving multiple genes, including
BAX and CASPASE5 (proapoptotic factors) and RAD50 (a
DNA repair gene) [27].
5.2.2. Aberrant Somatic Hypermutation (ASHM). Bc e l l si n
the germinal centre (GC) are subjected to a physiological
phenomenon known as “somatic hypermutation” (SHM),
which involves the introduction of single nucleotide sub-
stitution into their IgV genes [47]. It involves not only the
IgH gene but also nonimmunoglobulin genes such as BCL6
and Fas/CD95. In more than 50% of DLBCLs, SHMs can
also aﬀect some proto-oncogenes such as PAX5, PIM-1,
RhoH/TTF,a n dc-MYC gene, which are involved in the path-
ogenesis of lymphoid neoplasms including some cases of
PTLD [47].
5.2.3. Other Genetic Alterations
BCL6 Gene. The BCL6 gene is located on chromosome 3q27
and encodes a transcriptional repressor [48]. BCL6 rear-
rangement is very rarely seen in PTLDs, although it is the
target of SHM in approximately 50% of PTLDs [14, 19].
c-MYC Gene. c-MYC gene is located on chromosome 8q24
and is the target of chromosomal breaks in most posttrans-
plant Burkitt’s lymphomas (PT-BL) [14, 49].
BCL2 Gene. BCL2 gene, an antiapoptotic gene, is located on
chromosome 18q21. Although the BCL2 is ampliﬁed in a
proportion of PTLDs, its rearrangement is a very rare event
in PTLDs [14, 50].
TP53 Gene. The TP53 gene is a tumour suppressor gene lo-
cated on 17p13.1 and is mutated or deleted in a small pro-
portion of mPTLDs (DLBCL) [16].
IGH Gene. IGH gene is located on 14q32 and breakpoints
involving the gene are detected in a small proportion of6 Advances in Hematology
Table 4: Summary of diﬀerent genetic alterations among PTLDs.
Genetic alteration Frequency
BCL6 gene
(1) Rearrangement Rare in PTLD
(2) SHM 50% of PTLD
c-Myc gene rearrangement 100% PT-BL
BCL2 gene
(1) Rearrangement Very rare in PTLD
(2) Ampliﬁcation A proportion of PTLD
P53 gene mutation/deletion Small proportion of mPTLD
Translocations involving IG genes A small proportion of PTLD. Rarely in ﬂorid follicular hyperplasia in
posttransplant setting
PAX5 gene
(1) Rearrangement Very rare in PT-DLBCL
(2) SHM Very rare in PT-DLBCL
(3) Ampliﬁcation A proportion of PTLD
Chromosomal gains
(1) 3q27, 7q, 8q24, 12q, 12p, 18q21, 21q
(2) 5p and 11p PT-DLBCL = iDLBCL
(3) 6q25.3 Recurrent in PT-BL
(4) 1q, 11q, and of chromosome 7 PT-DLBCL
Chromosomal loss
(1) 1p, 6q, 9p, and 17p13 Common to PTLD and lymphomas immune competent patients
(2) 4q, 17q, and Xp In PTLD but not common in other lymphomas
(3) 12p, 4p, 4q, 12q, 17p, and 18q Frequent in PT-DLBCL
(4) 11q25 Recurrent in PT-BL
(5) 2p16.1 (FRA2E) 30% of PT-DLBCL (both in EBV positive and negative cases)
(6) 17p PT-DLBCL
Aberrant hypermethylation of
(1) MGMT 75% pPTLD and 93% mPTLD.
(2) DAP-kinase 75% mPTLD
(3) TP73 20% mPTLD
(4) SHP1 ∼77% PT-DLBCLs, 75% pPTLDs, 66% PT-BLs
(5) CDKN2A A small proportion of mPTLD
iDLBCL: immunocompetent diﬀuse large B cell lymphoma, mPTLD: monomorphic posttransplant lymphoproliferative disorders, pPTLD: polymorphic
posttransplant lymphoproliferative disorders, PT-BL: posttransplant Burkitt lymphoma, PT-DLBCL: posttransplant diﬀu s el a r g eBc e l ll y m p h o m a ,S H M :
Somatic hypermutation.
PTLD and rarely in ﬂorid follicular hyperplasia in post-
transplant setting [14].
PAX5 Gene. PAX5 is the target of t(9;14)(p13;q32) as well
as ASHM in a very small proportion of mPTLD (DLBCL)
[51, 52] .Ap r o p o r t i o no fP T L D sh a sa l s ob e e nr e p o r t e dt o
have PAX5 gene ampliﬁcation [53].
Other Chromosomal Changes. Comparative genomic hybri-
disation (CGH) analysis of PTLDs highlights some genetic
changes similar to those occurring in the lymphoma of
immunocompetent patients; for example, gains of 3q27,
7q, 8q24, 12q, 12p, 18q21, and 21q and losses of 1p, 6q,
9p, and 17p13. In addition, PTLDs show losses of 4q, 17q
and Xp that are not common in other lymphomas [50,
53]. It has been demonstrated that posttransplant-DLBCLs
(PT-DLBCLs), with a frequency similar to iDLBCLs, show
gains of chromosomes 5p and 11p. Moreover, deletions of
12p, 4p, 4q, 12q, 17p, and 18q are frequently seen in PT-
DLBCLs [53]. The ﬁnding that iDLBCLs and a proportion
of PTLDs (especially PT-DLBCLs) share some histogenetic
and pathogenetic pathways is reinforced by the presence of
recurrentchromosomalaberrationscommontobothPTLDs
and iDLBCLs [54]. In addition, recurrent deletions on 11q25
and gains on 6q25.3 were observed in PT-BLs [53]. Rinaldi et
al. [55] using high-density genome-wide SNP-based arrays,
reported similar genomic complexity among PT-DLBCLs,
HIV-DLBCLs, and iDLBCLs. Nonetheless, PT-DLBCLs dis-
played a genomic proﬁle with distinctive features. It has
been reported that the del(13q14.3) targets the locus cod-
ing for diﬀerent noncoding RNAs [56]. The absence of
del(13q14.3)inPT-DLBCLsisthemostsigniﬁcantdiﬀerence
between PT-DLBCLs and iDLBCLs [55, 57]. Del(13q14.3) is
thought to be involved in immunosurveillance escape in the
view that immunodeﬁciency-related lymphomas including
PTLDs lack del(13q14.3) [55].Advances in Hematology 7
PT-DLBCLs have IgV mutational status and gene expres-
sion proﬁles similar to post-GC B cells [3, 20]. Nonetheless,
iDLBCLs of post-GC phenotype display genetic lesions that
arediﬀerent fromPT-DLBCLs [55, 58,59].PT-DLBCLshave
been reported to have gains of 1q, 11q, and of chromosome
7, in addition to losses at 17p (TP53)[ 55]. Compared with
PT-DLBCLs, iDLBCLs were found to be more frequently
associated with gains of 18q (BCL2 and NFATC1), and
LOH at 6q21-q22 (approximately 7Mb telomeric from
PRDM1(BLIMP1)) and at 6p21.32-p21.33 (HLA-DR locus)
[55].
Craig et al. [60]u s e dA ﬀymetrix HU133A GeneChips
to show that EBV-positive mPTLDs overexpress several
interferon-induced genes as compared to EBV-negative
mPTLDs. Furthermore, EBV-negative PTLDs overexpress
genes corresponding to the B-cell receptor signalling path-
ways and a group of proliferation-related genes. These
suggest that EBV-negative PTLDs are biologically distinct
from EBV-positive PTLDs and are more similar to iDLBCL
[60].
When compared with EBV-negative PT-DLBCLs, EBV-
positive PT-DLBCLs have been described as having less
recurrent lesions. However, del(2p16.1) is common in both
EBV-negative and positive PT-DLBCLs [60].
“Fragile sites” are regions with marked genomic instabil-
ity, present throughout the genome, that are often the sites of
DNA breakage in malignant tumours and in cells exposed
to speciﬁc chemical agents [61]. PT-DLBCLs have been
described to have frequent interstitial deletions at 1p32.2,
2p16.1, 3p14.2, 4p14, 14q13.2, 20p12.3, and 20q13.32. Some
of these deletions involve fragile sites such as FRA1B, FRA2E,
andFRA3B.Del(2p16.1)(FRA2E)isthemostcommonaber-
ration in PT-DLBCLs, and the involvement is signiﬁcantly
higher than in iDLBCLs [55]. Some viruses including EBV
and HHV-8 have been shown to incorporate themselves into
the host genome, mainly at fragile sites, resulting in local
genomic instability at the insertion sites [55]. Iatrogenically
immunosuppressed posttransplant patients are more sus-
ceptible to a wide range of viruses which could integrate
into the genome, particularly at these fragile sites [55]. The
dissimilar pattern of breakage at fragile sites reported in PT-
DLBCLsandHIV-DLBCLsmightbeduetodiﬀerencesinthe
integration sites for various viruses [55].
5.2.4. Epigenetic Alteration (DNA Hypermethylation).
Hypermethylation is an epigenetic phenomenon that alters
the gene activity without changing its base sequences and is
accomplishedthroughDNAmethyltransferaseenzyme[62].
Aberrant hypermethylation (AH), which is a mechanism
for tumour suppressor gene silencing alternative to deletion
and/or mutation, has been implicated in the pathogenesis of
lymphoproliferative disorders in the posttransplant setting
[63].
Hypermethylation of Death-Associated Protein Kinase (DAP-
k). DAP-k is a serine-threonine kinase, which plays an im-
portant role in apoptosis triggered by TNFα,I N F γ,a n d
the FAS ligand. About 75% of mPTLDs display DAP-k
hypermethylation [64].
Hypermethylation of O6-Methylguanine-DNA Methyl-Trans-
ferase (MGMT). MGMT is one of the DNA repair genes
t h a ts e r v e st op r o t e c ta g a i n s tD N Ad a m a g e .M G M Ti s
methylatedinnearly75%and93%polymorphicPTLDs,and
mPTLDs respectively [65].
Hypermethylation of P73. P73 is a tumour suppressor gene
that bears some functional and structural resemblance to
TP53.Itplaysaroleincellcycleregulationandapoptosisand
is hypermethylated in about 20% mPTLDs [63].
Hypermethylation of P16. P16 is a tumour suppressor gene
located on chromosome 9p21. It hinders the G1-S cell cycle
transition by inhibiting the phosphorylation of Retinoblas-
toma protein. Martin et al. [66] described downregulation
of P16/INK4a in subsets of mPTLDs (DLBCLs) that had an
aggressive course but were not associated with EBV. There is
a rare case report of an EBV-positive mPTLD (plasmablastic
type) that showed P16 hypermethylation [67].
Hypermethylation of SHP1 Gene. The SHP1 gene is located
on chromosome 12p13 and encodes the SHP1 protein. The
protein is expressed in hematopoietic cells and potentiates
its negative eﬀect on cell cycle regulation by inhibiting the
JAKs/STATs pathway. In B-lymphocytes, therefore, it inhibits
proliferation, and its deﬁciency through AH results in
overgrowth[68].Cerrietal.[69]r epo rt edSHP1methylation
in 76.5% of the PT-DLBCLs, 75% of the polymorphic
PTLDs, 66% of the PT-BLs, and in a case of PT-myeloma.
5.3. Antigen Stimulation. Antigenic stimulation plays an
important role in the pathogenesis of immunodeﬁciency-
associated lymphomas. Under normal circumstances B cells
expresstheB-cellreceptor(BCR),andthelossofafunctional
receptor through the acquisition of mutations results in
apoptosis [47]. It has been demonstrated that EBV, through
expression of LMP2A which simulates a BCR, protects
BCR-lacking GC B cells from death, leading to lymphoma
development [47]. There are a few reports of the existence
of EBV-negative PTLDs that lack expression of sIg, pointing
to the possibility of as yet unidentiﬁed genetic mechanisms
that may rescue EBV-negative, BCR-lacking lymphocytes
[20]. Molecular signs of antigen stimulation are evident in
a fraction of PTLDs that exhibit a functional BCR [47].
5.4. Role of Microenvironment
5.4.1. Role of Plasmacytoid Dendritic Cells (PDCs). PDCs
are potent antigen-presenting cells that originate from the
hematopoieticstemcellsinthebonemarrowundertheeﬀect
of some cytokines, principally Flt3L [70]. In the posttrans-
plant scenario, EBV-stimulated PDCs produce insuﬃcient
concentrations of IFN-α. Furthermore, the numbers of
circulating blood PDC precursors are reduced in renal and
cardiac transplant recipients. These are thought to play a sig-
niﬁcant role in the development of lymphoproliferative dis-
orders [71, 72]. In addition, EBV-stimulated PDCs produce
the immunosuppressive cytokine IL-10, thereby allowing the8 Advances in Hematology
virus-infected B cells to escape immunorecognition [73]. IL-
10 inhibits expression of costimulatory molecules, which in
turn results in inability of monocytes and macrophages to
activate T cells [74]. In addition, IL-10 suppresses the pro-
duction of IFN-α and IFN-γ by PDCs, T cells, and NK cells.
It also has an inhibitory eﬀect on antigen-speciﬁc activation
and proliferation [75]. PDCs numbers are increased in some
malignant neoplasms including cutaneous T-cell lymphoma
[76]. PDCs are markedly decreased in number and are
qualitatively altered in non-Hodgkin lymphoma, compared
with reactive lymph nodes [76]. However, in some cases
of classical Hodgkin lymphoma (cHL), there are increased
numbers of PDCs present which may be attributed to the
cytokinesreleasedinthemicroenvironmentofcHL[76].The
observation of PDC clusters in tumour samples suggests that
PDCs may also play an important role in the pathogenesis
of cutaneous marginal zone B-cell lymphoma [77]. Based
on the ﬁnding of signiﬁcantly higher numbers of PDCs in
the tumour microenvironment of early lesions of B-PTLDs
compared to polymorphic and monomorphic lesion, and in
PT-DLBCLcomparedtoiDLBCL,PDCshavebeensuggested
to play a pathogenetically relevant role in PTLDs [78].
5.4.2. Role of Treg Cells. Treg cells are CD4+ and CD25+ T
lymphocytesthatareasubsetofimmunoregulatorycells,and
have the ability to suppress immune responses. There is a
subpopulation of Treg cells which express CD8 and not CD4
[79]. When Treg cells undergo activation via their TCR, they
inhibit the proliferation of CD4+ and CD8+ Tl y m p h o c y t e s ,
through the release of cytokines such as IL-10 and TGF-β
[80, 81]. The intratumoural Treg cells have been shown to
have an inhibitory eﬀect on the production and release of
perforin and granzyme B, which is necessary for the eﬀector
functions of CD8+ cells and cytotoxic T-cell-mediated lysis
of tumour cells [82]. Treg cells are also known to have a
direct eﬀect on B lymphocytes and inhibit the production of
immunoglobulins [83]. Treg cells can suppress the growth
of some tumours in addition to their role in suppressing
the antitumour immune response [84]. Higher numbers of
Tregcellshavebeendescribedaspredictorsofbothimproved
survival in follicular lymphoma and therapeutic response
[85].Tregcellsarefoundinhighernumbersintissuesamples
ofB-celllymphomasascomparedtoreactivelymphnodesor
tonsils.ThisisthoughttobeduetotheattractionofTregcells
to the tumour microenvironment through CCL22 secreted
by the lymphoma cells [85, 86]. It has been previously
shown that in recipients of solid organ transplants who are
on multiple immunosuppressive drugs, the levels FOXP3+
Treg cells reduce in the peripheral blood, possibly due to
redistribution into tissues and lymphoid organs [87]. The
numbers of Treg cells in the tumour microenvironment
of PTLDs have been shown to have no impact on patient
survival [88].
6. Conclusion
PTLDs are group of diseases that range from benign
polyclonal to malignant monoclonal lymphoid prolifera-
tions. Genetic and epigenetic alterations as well as viruses,
notably EBV, contribute towards the development of
PTLDs.Commongeneticrearrangementswhicharefrequent
in immune competent lymphoma are rare in PTLDs.
Microenvironment-resident PDCs and Treg cells are likely to
play a critical role in the pathogenesis of PTLDs. Therefore,
further studies investigating the cytokines secreted by PDCs
and Teg cells are required to substantiate and further clarify
their precise role in the pathogenesis of PTLD.
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